Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

NCT05308264 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT05308264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05308264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 12, 2022
Completion date
December 31, 2026
Enrollment
86 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

low risk myelodysplastic syndromes